California Senate Bill SB39

California 2025-2026 Regular Session

• Introduced: 12/3/24
• Refer: 1/29/25
• Refer: 2/11/25
• Report Pass: 3/19/25
• Engrossed: 3/28/25
• Refer: 4/28/25
• Refer: 5/8/25
• Refer: 6/12/25
• Report Pass: 6/18/25
• Enrolled: 9/11/25
• Chaptered: 10/1/25
• Passed: 10/1/25

Caption

An act to amend Sections 108980 and 108982 of the Health and Safety Code, relating to public health, and declaring the urgency thereof, to take effect immediately.

Impact

The bill's enactment would have significant implications for public health and safety, particularly for women experiencing recurrent vaginal infections. By acknowledging that boric acid is recognized in medical guidelines as a valuable treatment for such conditions, this legislation provides an avenue for patients to access necessary treatments while simultaneously safeguarding their health by preventing misuse during pregnancy. The impact extends to the cosmetic industry, as companies would need to adapt their products to align with these new regulatory requirements and ensure proper labeling and safety instructions are followed.

Summary

Senate Bill No. 39, also known as the Cosmetic Safety Bill concerning vaginal suppositories, seeks to amend the Health and Safety Code in California regarding the regulations of cosmetic products, particularly those containing boric acid. This legislation extends the existing prohibition on the sale of cosmetic products containing specific intentionally added ingredients, including boric acid, to vaginal suppositories until January 1, 2035. The bill aims to ensure that products containing boric acid carry appropriate warnings about their use during pregnancy and other health conditions, mandating labels that convey potential risks associated with the product's use.

Sentiment

The sentiment surrounding SB 39 appears to be largely supportive among health professionals and advocates for women's health. By reinforcing safety regulations and enhancing product labeling, the bill reflects a commitment to consumer protection and informed choice. However, there are underlying tensions regarding the balance between accessibility to crucial health products and the necessary precautions to safeguard vulnerable populations, particularly pregnant individuals. Advocates argue for the necessity of continued access to boric acid treatments, while critics may express concerns over potential health risks.

Contention

Notably, the discussions surrounding SB 39 highlight a contention between the urgency to regulate potentially hazardous ingredients and the need for effective treatment options for women's health issues. There are concerns about whether the regulations may limit access to effective treatments. Additionally, while the bill provides for exemptions for products that may become FDA regulated, questions remain on how this transition will affect consumers and the availability of essential health products. This legislation underscores a nuanced debate about product safety and the importance of continued research and regulation.